The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia

Launched by WESTERN UNIVERSITY, CANADA · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help people with cervical dystonia, a condition that causes involuntary neck muscle contractions. The main treatment for this condition is botulinum toxin injections, which can lose their effectiveness over time. In this study, researchers want to see if switching from the usual botulinum toxin brands (like Botox or Xeomin) to a different one called Dysport can help patients experience longer relief from their symptoms. Patients who feel their current treatment isn’t lasting long enough may be eligible to participate.

To qualify for the study, participants must be 18 years or older, have been diagnosed with isolated cervical dystonia, and have experienced some relief from their current treatment but find it wears off within eight weeks. The trial will involve giving treatments every three months for a total of three injections, with some patients receiving Dysport and others continuing with their original treatment, all while keeping the details of their treatment a secret from them to ensure unbiased results. Participants will visit local clinics for their treatments and monitoring, and the study is not yet recruiting patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years or above with a diagnosis of isolated CD
• • Experience efficacious relief with a waning time of ≤8 weeks post-injection
• • Must have received the same dose and injection pattern of onaBoNT-A or incoBoNT-A for at least 3 injection cycles prior to study initiation with an injection cycle of 12 weeks
• Exclusion Criteria:
• • Require a total dose \<80 U or \>300 U ona/incoBoNT-A
• • Pure reterocollis or suspected secondary non-responsiveness
• • No interest in switching between BoNT-A formulations
• • Prolonged history of dysphagia
• • History of poor response to BoNT-A or BoNT-B
• • Inability to complete study visits or sign informed consent
• • Pregnancy
• • Known resistance or contradictions to any BoNT-A
• • Known hypersensitivity to BoNT-A or related compound